Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer crawled time : 12:00 save search
RSNA and GE HealthCare Bring Advanced Mammography Technology to Tanzania to Improve Access and Help Address Breast Cancer Mortality Rate
Published: 2024-04-16 (Crawled : 12:00) - prnewswire.com
GEHC | $85.88 -0.29% -0.29% 1.8M
|
n/a
|
| O: -1.69%
H: 0.0%
C: 0.0%
breast cancer technology advanced
Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting
Published: 2024-04-11 (Crawled : 12:00) - globenewswire.com
PVCT | $0.1675 -15.0% 52K
|
Manufacturing
|
| O: 0.0%
H: 17.21%
C: 7.19%
pv-10 presentation cancer immunotherapy for meeting
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
ONCY | $1.07 0.94% 0.93% 260K
|
Health Technology
|
| O: 1.85%
H: 0.0%
C: 0.0%
biotech fda breast cancer for meeting trial submission
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
MNPR | $0.729 -3.44% -3.57% 180K
|
Health Technology
|
| O: 4.79%
H: 5.3%
C: 3.41%
mnpr-101 cancer for trial advanced
ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
PRPH | $7.47 21.37% 17.6% 190K
|
Health Technology
|
| O: -7.22%
H: 2.98%
C: 1.49%
management test cancer
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
QLGN | $0.3075 -3.88% -4.03% 190K
|
Health Technology
|
| O: -2.03%
H: 2.35%
C: -2.76%
association direct cancer research meeting
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
BCTX | $2.19 -5.6% -5.94% 140K
|
Professional, Scientific, and T...
|
| O: -3.83%
H: 0.0%
C: 0.0%
breast cancer preclinical for
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
MTEM | $1.59 -10.67% -11.95% 54K
|
Health Technology
|
| O: 9.73%
H: 0.49%
C: -8.87%
mt-6402 association tumors cancer research for molecular study
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
QLGN | $0.3075 -3.88% -4.03% 190K
|
Health Technology
|
| O: 3.2%
H: 0.0%
C: -0.28%
qn-302 association positive cancer research meeting therapeutics
iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
ICAD | $1.57 -3.68% -3.82% 130K
|
Technology Services
|
| O: 5.7%
H: 11.98%
C: 7.78%
precision breast health cancer risk solutions for
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
BCTX | $2.19 -5.6% -5.94% 140K
|
Professional, Scientific, and T...
|
| O: 1.77%
H: 0.0%
C: 0.0%
breast cancer system
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
ORIC | $9.47 -0.73% -0.74% 200K
|
Health Technology
|
| O: -1.25%
H: 0.0%
C: -2.71%
association cancer pharmaceuticals research preclinical for meeting
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
CORT M | $23.4 1.08% 1.07% 710K
|
Health Technology
|
| O: 2.41%
H: 0.0%
C: -4.98%
cancer trial
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
INMB | $9.16 -4.38% -4.59% 120K
|
Health Technology
|
| O: 0.97%
H: 3.96%
C: 0.0%
inb03 breast cancer treatment
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
CCCC | $6.84 -0.29% -0.29% 1.2M
|
Health Technology
|
| O: -1.57%
H: 0.0%
C: 0.0%
cft1946 association approved cancer care research preclinical for meeting therapeutics
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
TPST | $3.33 -0.3% -0.3% 470K
|
Manufacturing
|
| O: 8.39%
H: 2.71%
C: -12.96%
tpst-1120 tumors positive cancer publication research communications trial advanced
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
CADL | $5.89 1.2% 1.19% 1.1M
|
|
| O: 26.87%
H: 276.85%
C: 215.27%
can-2409 positive cancer pancreatic trial therapeutics
The Oncology Institute and Healthly Forge Strategic Alliance to Elevate Cancer Care Access to Healthly Patients Across Southern California
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
TOI | $1.175 -1.26% -1.28% 59K
|
|
| O: 2.01%
H: 0.66%
C: -1.32%
california institute cancer care
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:00) - biospace.com/
MRK | $125.06 -0.9% 0.0% 5.6M
|
Health Technology
|
| O: 0.24%
H: 0.08%
C: -2.42%
mk-1084 keytruda lung merck cancer cell treatment trial
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment
Published: 2024-04-04 (Crawled : 12:00) - biospace.com/
EXAS | $63.845 -2.3% -2.36% 3.5M
|
Health Technology
|
| O: 0.01%
H: 0.24%
C: -4.41%
cancer treatment tumor sciences
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.